Stallergenes Sa (STLEF) 66.3000 $STLEF Global Ragweed

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stallergenes Sa (STLEF) 66.3000 $STLEF

Global Ragweed Allergy Pipeline Review 2015 - 5 Companies & 7 Drug Profiles
M2 - Mon Oct 05, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q25wck/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anergis SA - Biomay AG - Circassia Pharmaceuticals Plc - Immunomic Therapeutics, Inc. - Stallergenes S.A. Drug Profiles - Allergen for Ragweed Pollen Allergy - AllerR - BM-34 - Multi-LAMP-Vax - PL-101 - ragweed hypoallergenic vaccine - Vaccine for Asthma, Ragweed Allergy and Rhino-Conjunctivitis For more information visit http://www.researchandmarkets.com/research/q2...ed_allergy

House Dust Mite Allergy Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Oct 02, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2n2t5/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Anergis SA - Biomay AG - Circassia Pharmaceuticals Plc - DBV Technologies S.A. - HAL Allergy BV - Stallergenes S.A. Drug Profiles - AllerDM - Allergen for House Dust Mite Allergy - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - BM-35 - MK-8237 - PL-103 - STG-320 - Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy For more information visit http://www.researchandmarkets.com/research/f2..._dust_mite

Global Birch Pollen Allergy Pipeline Review 2015
M2 - Mon Sep 07, 2:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k7vkkl/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Anergis SA - Biomay AG - Circassia Pharmaceuticals Plc - HAL Allergy BV - Stallergenes S.A. Drug Profiles - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - AllerT - Birch-SPIRE - BM-31 - PL-102 - rBet v1 - rBet v1-FV - STG-210 For more information visit http://www.researchandmarkets.com/research/k7...rch_pollen

Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen

Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g4fb7t/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Stallergenes S.A. Drug Profiles - AllerR - BM-34 - Drug for Ragweed Pollen Allergy - Multi-LAMP-Vax - PL-101 - Pollinex Ragweed - ragweed hypoallergenic vaccin - Ragweed-SPIRE For more information visit http://www.researchandmarkets.com/research/g4...ed_allergy

Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy

Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jjl3r/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Bial - Portela & Ca, S.A. - BioTech Tools s.a. - Circassia Pharmaceuticals plc - Greer Laboratories, Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Laboratorios LETI S.L. - Stallergenes S.A. Drug Profiles - Acaroid - AL-0704rP - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergovac - AllerT - Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Avanz Phleum Pratense - Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Depigoid Birch - Dermatophagoides Pteronyssinus Allergen Extract - gpASIT TM - Grass Pollen Allergoid - Grass-SPIRE - House Dust Mite-SPIRE - JRC2-LAMP-vax - MK-8237 - Olea Europaea Pollen Extract - Pollinex Quattro Grass - Ragweed Pollen Extract - rBet v1 - rBet v1-FV - rPhleum For more information visit http://www.researchandmarkets.com/research/8jjl3r/allergic

Global Allergic Asthma Pipeline Review 2015
M2 - Wed May 27, 11:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7j82mp/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Asmacure Ltee - BioTech Tools s.a. - Fountain Biopharma Inc. - Genentech, Inc. - Infinity Pharmaceuticals, Inc. - Kineta, Inc. - Marinomed Biotechnologie GmbH - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Panacea Biotec Limited - Peptinnovate Limited - Pharmaxis Limited - Portola Pharmaceuticals, Inc. - Protectimmun GmbH - Pulmatrix, Inc. - Stallergenes S.A. - sterna biologicals Gmbh & Co KG - Verona Pharma Plc For more information visit http://www.researchandmarkets.com/research/7j...gic_asthma
PTLA: 43.31 (+0.76), INFI: 8.37 (+0.48), NVS: 91.90 (-0.71), ARRY: 5.09 (+0.13)

Global House Dust Mite Allergy Pipeline Report 2015 - 7 Companies & 9 Drug Profiles
M2 - Wed May 20, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s4jvmr/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - DBV Technologies S.A. - HAL Allergy BV - Stallergenes S.A. Drug Profiles - AllerDM - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - allergenic pollen extract of timothy - BM-35 - House Dust Mite-SPIRE - MK-8237 - PL-103 - S-524101 - Viaskin House Dust Mite For more information visit http://www.researchandmarkets.com/research/s4..._dust_mite

Stallergenes Continues To Play Games With Minority Shareholders
Early Retiree - at Seeking Alpha - Fri May 15, 10:04AM CDT


Stallergenes-Greer Takeover Getting Messy
Early Retiree - at Seeking Alpha - Thu Apr 09, 5:30PM CDT


Is The Stallergenes-Greer Merger Good For Minority Shareholders?
Early Retiree - at Seeking Alpha - Fri Mar 06, 10:40AM CST


Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Mon Mar 02, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4g5s4/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering. Birch Pollen Allergy - Pipeline Review, H1 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - HAL Allergy BV - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerT - Birch-SPIRE - BM-31 - Drug for Birch Pollen Allergy - PL-102 - rBet v1 - rBet v1-FV For more information visit http://www.researchandmarkets.com/research/d4...rch_pollen

What To Buy In Europe
Early Retiree - at Seeking Alpha - Sun Feb 22, 4:01AM CST

SNY: 48.75 (+0.03)

Global Cedar Pollen Allergy Pipeline Therapeutics Review, H2 2014 - 8 Companies & 11 Drug Profiles
M2 - Wed Jan 07, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrv8ls/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. Drug Profiles - AllerJ - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - Japanese Cedar Hypoallergenic Vaccine - JCC-LAMP-Vax - JRC-LAMP-Vax - MC-LAMP-Vax - Pollinex Quattro Japanese Cedar - RGI-1001 - TO-206 - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/hr...dar_pollen

Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 43.31 (+0.76), AZN: 32.23 (-0.16), INFI: 8.37 (+0.48), NVS: 91.90 (-0.71)

Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 50.95 (-0.07)

STALLERGENES And ActoGenix To Develop An Innovative New Class Of Oral Allergy Treatments
PR Newswire - Thu Nov 20, 11:00AM CST
STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today that it has exercised the option to pursue the exclusive development of an innovative new class of oral allergy treatments in partnership with ActoGeniX NV, creator of ActoBiotics(TM), in accordance with the contract signed in December 2013.

Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 50.95 (-0.07), NVS: 91.90 (-0.71)

Update: Stallergenes Stable As Usual, But Growth Lies Ahead
Early Retiree - at Seeking Alpha - Thu Oct 23, 1:42PM CDT


Scroll down for more posts ▼

Top 10 Most Recent News Articles

HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 111

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 36

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 358

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 288

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 438

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 395

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
rshangout.com/blog/news?page=2">More News Articles